



Deadline	Tue 07 Mar 2023 12:00 (noon) CET Pre-proposals (IOCB deadline Tue 28 Feb 2023) Tue 27 Jun 2023 12:00 (noon) CEST Full-proposals (IOCB deadline Fri 23 Jun 2023)
Call name	The EU Joint Programme – Neurodegenerative Disease Research (JPND) Call 2023: “Large scale analysis of OMICS data for drug-target finding in neurodegenerative diseases”
www	JPND: https://www.neurodegenerationresearch.eu/initiatives/annual-calls-for-proposals/2023-research-call-on-large-scale-analysis-of-omics-data-for-drug-target-finding-in-neurodegenerative-diseases/ MEYS: https://www.msmt.cz/vyzkum-a-vyvoj-2/iniciativa-spolecneho-programovani-neurodegenerativni-4
Focused on	Fundamental, translational research
PI	Consortium of 3–6 (7 when from underrepresented countries: Czech Republic, Hungary, Poland, Slovakia or Turkey) partners (represented by the leaders of individual research groups) represented by a coordinator.
Eligible organisation	Research organisations, universities, hospitals, other health and social care settings, commercial sector and SMEs - national restriction may apply. Participating countries: Austria, Belgium, Canada, Czech Republic, France, Germany, Hungary, Ireland, Israel, Italy, Luxembourg, Netherlands, Poland, Slovakia, Spain, Sweden, Switzerland, Turkey.
Target group	Multinational research groups collaboration: Consortium 3-6 partners from at least. 3 countries, with participation of underrepresented countries up to 7 partners, max. 2 partners from the same country in 1 consortium
Expected outputs	Not specified (publications, etc.)
Call opens	04 Jan 2023
IOCB deadline	Tue 28 Feb 2023 Pre-proposals Fri 23 Jun 2023 Full-proposals
Final deadline	Tue 07 Mar 2023 12:00 (noon) CET Pre-proposals One joint proposal per consortium- submission website: https://ptoutline.eu/app/jpnd2023 Czech participants: MEYS: statutory declaration of each participant and planned budget (using the prescribed form) to be submitted preferably as digitally signed documents through the MEYS data box (ID <i>vidaawt</i>). Tue 27 Jun 2023 12:00 (noon) CEST Full-proposals - same as pre-proposals.
Evaluation results	Results of Pre-proposals assessment – end of May 2023 Results of Full-proposals assessment – Oct 2023
Signature of agreement	
Earliest date of implementation	Early 2023
Latest date of implementation	
Sustainability	none
Reporting	Brief annual scientific report in Jan of each year and final scientific progress report within 3 months from project end. for Czech participants – MEYS, annual scientific and financial reports due 31 January of the following years);
Project duration (min-max)	up to 36 months
Allocation for the call	Total 16.5 M EUR, MEYS – 1 million EUR
Project budget (min-max)	No restriction
Success rate	12 % (2019)
Eligible costs	Czech participant: §2 of the Act. No 130/2002 Coll. direct costs: personnel, consumables, equipment, travel, other costs indirect costs: overheads max 25 % (flat rate) of direct costs without subcontracting Only the research and knowledge-dissemination organizations are eligible for the MEYS support.
Reimbursement	100 % for fundamental/basic research activities, 50 % for applied research activities and 25 % for experimental development activities

Mode of funding	ex-ante
Language of application	English/Czech for MEYS
Provider	<p>Consortium of 18 providers from 18 countries (for Czech participants – MEYS) Ministry of Education, Youth and Sports of the Czech Republic (MEYS/MŠMT), Prague, www.msmt.cz Mgr. Daniel Hanšpach, +420 234 811 360, daniel.hanspach@msmt.cz JPND Joint Call Secretariat: DLR-PT, Health Division (De); www.jpnd.eu Dr. Sabrina Voß or Dr Sara Breid; jpnd@dlr.de; (+49) 228-3821 2111</p>
Call identifier	JPND 2023
Call info	<p>The aim of the call is to establish a number of ambitious, innovative, multi-disciplinary and multi-national collaborative research projects that seek to improve the understanding of the complex and multifactorial pathogenesis of neurodegenerative diseases by applying multi-OMICS and Big data approaches in order to generate useful information for the diagnosis, treatment, prognosis, and drug discovery of neurodegenerative diseases.</p>
Conditions / Restrictions	<p>Proposals submitted under this call may include, but are not limited to, the following types of research:</p> <ul style="list-style-type: none"> • Using the potential from existing animal and cellular models and cohorts, including available data and biomaterial, for conducting large-scale OMICS approaches to unravel the interplay and interactions of molecules from multiple molecular levels driving disease pathogenesis. • Better understanding the complex and multi-factorial mechanisms of disease onset and progression as well as the corresponding influencing factors. • Translating the findings from Big Data analysis and multi-OMICS approaches to existing animal and cellular models, thereby enhancing the potential of these models. • Identification of new drug targets or novel starting points for pharmacological interventions and prevention. • Sharpening the current understanding of disease definition, thus leading to enhanced subclassification and better patient stratification. • Identification of novel and validation of already established biomarkers. <p>Proposals must also relate to any or several of the following neurodegenerative diseases: Alzheimer's disease and other dementias, Parkinson's disease and PD-related disorders, prion diseases, motor neuron diseases, Huntington's disease, spinocerebellar ataxia and spinal muscular atrophy. JPND is committed to Patient and Public Involvement, and proposals are expected to engage patients, carers and the public. Training of young researchers and mobility is encouraged.</p> <p>No annexes, CVs or Letter of Intent are allowed in the pre-proposals. Such information will be requested at the full-proposal stage.</p> <p>EU-13/Underrepresented countries: Czech Republic, Hungary, Poland, Slovakia, Turkey)</p>
Proposal consists of	<p>Joint Pre-proposal application form: (max 6 pages)</p> <ul style="list-style-type: none"> • Synopsis: application details, the consortium and a scientific summary (keywords, disease/s addressed, abstract) (max. 1 page) • Project description: aims, research questions, working hypothesis integrated into a description of the scientific background and of the present state of research, with special emphasis on transnational added value and specific expertise of the consortium members; some delineation of work plan, methodology (mostly expected in full proposal), references (max. 4 pages) • Budget overview –costs requested for each partner, brief description (max. 1 page) <p>CZ: MEYS requested documentation:</p> <ul style="list-style-type: none"> • Eligible Costs Specification • Statutory Declaration
Evaluation criteria	Relevance; Scientific quality; Transnational added value; International competitiveness; Deliverable outcomes; the criteria will be equally weighted.
Research areas	All research areas and expertise relevant to the topic.
Call workshop	
IOCB contact	<p>Please inform the IOCB Project Office (projectoffice@uochb.cas.cz) about your intention to apply. Do not hesitate to contact us for consulting, discussion or help.</p> <p>Veronika Palečková, veronika.paleckova@uochb.cas.cz, +420 220 183 266 Jitka Šilerová, jitka.silerova@uochb.cas.cz, +420 220 183 229 Blanka Collis, blanka.collis@uochb.cas.cz, +420 220 183 527</p>
Download documents	<p>JPND-2023_Summary JPND-2023_Call JPND-2023_Procedures JPND-2023_Pre-proposal_Form JPND-2023_CZspecific JPND-2023_MEYS_Costs_Specification</p>